High Risk Retinoblastoma: Prevalence and Success of Treatment in Developing Countries

References

• Dimaras H, Kimani K, Dimba E, et al. Retinoblastoma. Lancet 2012;379:1436–1446
   PubMed Web of Science ®Google Scholar
• Dimaras H, Dimba E, Gallie BL. Challenging the global retinoblastoma survival disparity through a collaborative research effort. Br J Ophthalmol 2010;94:1415–1416
   PubMed Web of Science ®Google Scholar
• Bowman RJC, Mafwiri M, Luthert P, et al. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer 2008;50:160–162
   PubMed Web of Science ®Google Scholar
• Canturk S, Qaddoumi I, Khetan V, et al. Survival of retinoblastoma in less-developed countries: impact of socioeconomic and health-related indicators. Br J Ophthalmol 2010;94:1432–1436
   PubMed Web of Science ®Google Scholar
• Chantada GL, Doz F, Orjuela M, et al. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer 2008;50:692–694
   PubMed Web of Science ®Google Scholar
• Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol 1999;83:1320–1323
   PubMed Web of Science ®Google Scholar
• Zhao J, Dimaras H, Massey C, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol 2011;29:845–851
   PubMed Web of Science ®Google Scholar
• Chantada G, Leal-Leal C, Brisse H, et al. Is it pre-enucleation chemotherapy or delayed enucleation of severely involved eyes with intraocular retinoblastoma that risks extraocular dissemination and death? J Clin Oncol 2011;29:3333–3334, 3335--3336
   PubMed Web of Science ®Google Scholar
• Chantada G, Fandiño A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 2003;40:158–161
   PubMedGoogle Scholar
• Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma following primary enucleation. J Clin Oncol 2013;31:1458–1463
   PubMed Web of Science ®Google Scholar
• Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113:2276–2280
   PubMed Web of Science ®Google Scholar
• Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 2009;133:1199–1202
   PubMed Web of Science ®Google Scholar
• Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996;77:1206–1213
   PubMed Web of Science ®Google Scholar
• World Development Indicators 2013. Washington, DC: The World Bank, 2013
   Google Scholar
• Sitorus RS, Moll AC, Suhardjono S, et al. The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet 2009;30:31–36
   PubMed Web of Science ®Google Scholar
• Shields CL, Honavar SG, Shields J, et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460–464
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993;77:544–548
   PubMed Web of Science ®Google Scholar
• Chantada G, Luna-Fineman S, Sitorus RS, et al. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer 2013;60:719–727
   PubMed Web of Science ®Google Scholar
• Chintagumpala M, Chevez-Barrios P, Paysse E, et al. Retinoblastoma: review of current management. Oncologist 2007;12:1237–1246
   PubMed Web of Science ®Google Scholar
• Kashyap S, Meel R, Pushker N, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer 2012;58:356–361
   PubMed Web of Science ®Google Scholar
• Kim JW, Kathpalia V, Dunkel IJ, et al. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 2009;93:463–467
   PubMed Web of Science ®Google Scholar
• Chantada GL, Dunkel IJ, de Dávila MTG, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol 2004;88:1069–1073
   PubMed Web of Science ®Google Scholar
• Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001;119:41–48
   PubMed Web of Science ®Google Scholar
• Chantada GL, Gonzalez A, Fandino A, et al. Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma. J Pediatr Hematol Oncol 2009;31:325–329
   PubMed Web of Science ®Google Scholar
• Finger PT, Harbour JW, Karcioglu Z. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol 2002;47:1–16
   PubMed Web of Science ®Google Scholar
• Chantada G, Antoneli CBG, Grundy R, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006;47:801–805
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994;73:692–698
   PubMed Web of Science ®Google Scholar
• Chantada GL, Casco F, Fandiño AC, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 2007;114:2083–2089
   PubMed Web of Science ®Google Scholar
• Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002;120:923–931
   PubMed Web of Science ®Google Scholar